Mutual of America Capital Management LLC Takes Position in PRA Health Sciences Inc (PRAH)

Mutual of America Capital Management LLC bought a new position in PRA Health Sciences Inc (NASDAQ:PRAH) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 30,826 shares of the medical research company’s stock, valued at approximately $2,807,000.

A number of other hedge funds have also recently added to or reduced their stakes in PRAH. Wells Fargo & Company MN grew its stake in shares of PRA Health Sciences by 55.8% during the 3rd quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock valued at $91,943,000 after buying an additional 432,449 shares during the period. Stephens Investment Management Group LLC grew its stake in shares of PRA Health Sciences by 236.9% during the 3rd quarter. Stephens Investment Management Group LLC now owns 391,672 shares of the medical research company’s stock valued at $29,834,000 after buying an additional 275,414 shares during the period. State Street Corp grew its stake in shares of PRA Health Sciences by 52.8% during the 2nd quarter. State Street Corp now owns 782,800 shares of the medical research company’s stock valued at $58,729,000 after buying an additional 270,530 shares during the period. Neuberger Berman Group LLC grew its stake in shares of PRA Health Sciences by 2,738.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 245,711 shares of the medical research company’s stock valued at $18,716,000 after buying an additional 237,055 shares during the period. Finally, Hood River Capital Management LLC grew its stake in shares of PRA Health Sciences by 31.5% during the 3rd quarter. Hood River Capital Management LLC now owns 815,141 shares of the medical research company’s stock valued at $62,089,000 after buying an additional 195,217 shares during the period. 97.39% of the stock is owned by hedge funds and other institutional investors.

In other PRA Health Sciences news, insider David W. Dockhorn sold 72,850 shares of the business’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The disclosure for this sale can be found here. Insiders have sold a total of 217,815 shares of company stock worth $19,690,710 in the last 90 days. Company insiders own 2.10% of the company’s stock.

PRA Health Sciences Inc (NASDAQ PRAH) opened at $85.43 on Friday. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. The firm has a market cap of $5,510.00, a price-to-earnings ratio of 47.99, a P/E/G ratio of 1.14 and a beta of 0.31. PRA Health Sciences Inc has a 1-year low of $57.72 and a 1-year high of $95.90.

Several brokerages have recently issued reports on PRAH. SunTrust Banks reissued a “buy” rating and set a $101.00 price objective on shares of PRA Health Sciences in a research note on Friday, October 27th. KeyCorp restated a “buy” rating and set a $100.00 target price on shares of PRA Health Sciences in a report on Wednesday, January 31st. Zacks Investment Research upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a report on Wednesday, January 17th. Mizuho set a $87.00 target price on shares of PRA Health Sciences and gave the company a “buy” rating in a report on Friday, December 1st. Finally, Robert W. Baird set a $94.00 target price on shares of PRA Health Sciences and gave the company a “buy” rating in a report on Friday, December 1st. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. PRA Health Sciences presently has an average rating of “Buy” and a consensus price target of $92.31.

WARNING: This piece was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2018/02/11/mutual-of-america-capital-management-llc-takes-position-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply